Wed. 8 May 2024, 6:41am ET
Benzinga
Biotech, News, Health Care, General
- Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed
- Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)
- 81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12
- Measures of symptom scores relative to baseline improved following a single 25mg dose administered with psychological support (n=22)